Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on May 20, 2008
Schizophrenia Bulletin 2008 34(4):611-612; doi:10.1093/schbul/sbn043
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
34/4/611    most recent
sbn043v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Syed Sheriff, R. J.
Right arrow Articles by Xia, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Syed Sheriff, R. J.
Right arrow Articles by Xia, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Pharmacological Interventions for Clozapine-induced Hypersalivation

Rebecca J. Syed Sheriff1,2, Katie Au3, Caroline Cahill4, Lorna Duggan5, Yanling He6, Victor Udu4 and Jun Xia7
2 Health Services and Population Research Department, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
3 King's College Hospital, Denmark Hill, London SE5 9RS, UK
4 St Andrew's Hospital, Spring Hill, Cliftonville, Northampton NNH1 5BE, UK
5 Developmental Disabilities Division, St Andrew's Hospital, Billing Road, Northampton, Northamptonshire NN1 5DG, UK
6 Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China
7 Cochrane Schizophrenia Group, University of Leeds, Leeds, West Yorkshire LS2 9LT, UK

The first 10% of the full text of this article appears below.


   Background
 
Clozapine is widely used for people with schizophrenia. Agranulocytosis, weight gain, and cardiac problems are serious problems associated with clozapine use. Hypersalivation, sometimes of a gross and socially unacceptable quantity, is also common (30%–80%).


   Objectives
 
To determine the clinical effects of pharmacological interventions for clozapine-induced . . . [Full Text of this Article]


   Search strategy
 

   Selection criteria
 

   Data collection and analysis
 

   Main results
 

   Reviewers' conclusions
 

   Implications for practice and research
 
1 To whom correspondence should be addressed; tel: (0)20-7848-0136, fax: (0)20-7848-5450, e-mail: rebecca.syed@iop.kcl.ac.uk.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?